\n 脱氧胞苷激酶(DCK)重组蛋白脱氧胞苷激酶(DCK)重组蛋白
适用生物\xa0\xa0 \xa0Homo sapiens (Human,人)
脱氧胞苷激酶(DCK)重组蛋白脱氧胞苷激酶(DCK)重组蛋白
产品应用\xa0\xa0 \xa0SDS-PAGE; WB; ELISA; IP.\xa0\xa0 \xa0规格\xa0\xa0 \xa050ug
分子量\xa0\xa0 \xa0n/a\xa0\xa0 \xa0价格\xa0\xa0 \xa0请咨询当地代理商
纯度\xa0\xa0 \xa0> 95% \xa0
来源\xa0\xa0 \xa0原核表达
Recombinant Deoxycytidine Kinase (DCK)
Recombinant Deoxycytidine Kinase (DCK)
FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!
FOR IN VITRO AND RESEARCH USE ONLY, NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES!
\t\t\t\t\t\t| Organism species | \t\t\tHomo sapiens (Human) | \t\t
\t\t\t\t\t| Product No. | \t\t\tRPC440Hu01 | \t\t
\t\t\t\t\t| Source | \t\t\tProkaryotic expression | \t\t
\t\t\t\t\t| Host | \t\t\tE.coli | \t\t
\t\t\t\t\t| Purity | \t\t\t> 95% | \t\t
\t\t\t\t\t| UOM | \t\t\t50ug | \t\t
\t\t\t\t\t| Predicted Molecular Mass | \t\t\tn/a | \t\t
\t\t\t\t\t| Predicted isoelectric point | \t\t\tn/a | \t\t
\t\t\t\t\t| Applications | \t\t\tSDS-PAGE; WB; ELISA; IP. | \t\t
\t\t\t\t\t| Endotoxin Level | \t\t\t<1.0EU per 1μg (determined by the LAL method) | \t\t
\t
\xa0
\t\t\t\t\t\t| Organism species | \t\t\tHomo sapiens (Human) | \t\t
\t\t\t\t\t| Product No. | \t\t\tRPC440Hu01 | \t\t
\t\t\t\t\t| Source | \t\t\tProkaryotic expression | \t\t
\t\t\t\t\t| Host | \t\t\tE.coli | \t\t
\t\t\t\t\t| Purity | \t\t\t> 95% | \t\t
\t\t\t\t\t| UOM | \t\t\t50ug | \t\t
\t\t\t\t\t| Predicted Molecular Mass | \t\t\tn/a | \t\t
\t\t\t\t\t| Predicted isoelectric point | \t\t\tn/a | \t\t
\t\t\t\t\t| Applications | \t\t\tSDS-PAGE; WB; ELISA; IP. | \t\t
\t\t\t\t\t| Endotoxin Level | \t\t\t<1.0EU per 1μg (determined by the LAL method) | \t\t
\t
\t\t\t\t\t\t| Organism species | \t\t\tHomo sapiens (Human) | \t\t
\t\t\t\t\t| Product No. | \t\t\tRPC440Hu01 | \t\t
\t\t\t\t\t| Source | \t\t\tProkaryotic expression | \t\t
\t\t\t\t\t| Host | \t\t\tE.coli | \t\t
\t\t\t\t\t| Purity | \t\t\t> 95% | \t\t
\t\t\t\t\t| UOM | \t\t\t50ug | \t\t
\t\t\t\t\t| Predicted Molecular Mass | \t\t\tn/a | \t\t
\t\t\t\t\t| Predicted isoelectric point | \t\t\tn/a | \t\t
\t\t\t\t\t| Applications | \t\t\tSDS-PAGE; WB; ELISA; IP. | \t\t
\t\t\t\t\t| Endotoxin Level | \t\t\t<1.0EU per 1μg (determined by the LAL method) | \t\t
\t
\t
\t\t\t\t\t| Organism species | \t\t\tHomo sapiens (Human) | \t\t
\t\t\t\t\t| Product No. | \t\t\tRPC440Hu01 | \t\t
\t\t\t\t\t| Source | \t\t\tProkaryotic expression | \t\t
\t\t\t\t\t| Host | \t\t\tE.coli | \t\t
\t\t\t\t\t| Purity | \t\t\t> 95% | \t\t
\t\t\t\t\t| UOM | \t\t\t50ug | \t\t
\t\t\t\t\t| Predicted Molecular Mass | \t\t\tn/a | \t\t
\t\t\t\t\t| Predicted isoelectric point | \t\t\tn/a | \t\t
\t\t\t\t\t| Applications | \t\t\tSDS-PAGE; WB; ELISA; IP. | \t\t
\t\t\t\t\t| Endotoxin Level | \t\t\t<1.0EU per 1μg (determined by the LAL method) | \t\t
\t\t\t
\t\t\t| Organism species | \t\t\tHomo sapiens (Human) | \t\t
\t\t\t
Organism species | Organism speciesOrganism species\t\t\t
Homo sapiens (Human) | Homo sapiens (Human)\t\t\t\t
\t\t\t| Product No. | \t\t\tRPC440Hu01 | \t\t
\t\t\t
Product No. | Product No.Product No.\t\t\t
RPC440Hu01 | RPC440Hu01\t\t\t\t
\t\t\t| Source | \t\t\tProkaryotic expression | \t\t
\t\t\t
Source | SourceSource\t\t\t
Prokaryotic expression | Prokaryotic expression\t\t\t\t
\t\t\t| Host | \t\t\tE.coli | \t\t
\t\t\t
Host | HostHost\t\t\t
E.coli | E.coli\t\t\t\t
\t\t\t| Purity | \t\t\t> 95% | \t\t
\t\t\t
Purity | PurityPurity\t\t\t
> 95% | > 95%\t\t\t\t
\t\t\t| UOM | \t\t\t50ug | \t\t
\t\t\t
UOM | UOMUOM\t\t\t
50ug | 50ug\t\t\t\t
\t\t\t| Predicted Molecular Mass | \t\t\tn/a | \t\t
\t\t\t
Predicted Molecular Mass | Predicted Molecular MassPredicted Molecular Mass\t\t\t
n/a | n/a\t\t\t\t
\t\t\t| Predicted isoelectric point | \t\t\tn/a | \t\t
\t\t\t
Predicted isoelectric point | Predicted isoelectric pointPredicted isoelectric point\t\t\t
n/a | n/a\t\t\t\t
\t\t\t| Applications | \t\t\tSDS-PAGE; WB; ELISA; IP. | \t\t
\t\t\t
Applications | ApplicationsApplications\t\t\t
SDS-PAGE; WB; ELISA; IP. | SDS-PAGE; WB; ELISA; IP.\t\t\t\t
\t\t\t| Endotoxin Level | \t\t\t<1.0EU per 1μg (determined by the LAL method) | \t\t
\t\t\t
Endotoxin Level | Endotoxin LevelEndotoxin Level\t\t\t
<1.0EU per 1μg (determined by the LAL method) | <1.0EU per 1μg (determined by the LAL method)\t\t\t
\xa0
\xa0
\xa0
\xa0
\t\t\t\t\t\t| Subcellular Location | \t\t\tn/a | \t\t
\t\t\t\t\t| Residues | \t\t\tn/a | \t\t
\t\t\t\t\t| Formulation | \t\t\tSupplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. | \t\t
\t
\t\t\t\t\t\t| Subcellular Location | \t\t\tn/a | \t\t
\t\t\t\t\t| Residues | \t\t\tn/a | \t\t
\t\t\t\t\t| Formulation | \t\t\tSupplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. | \t\t
\t
\t
\t\t\t\t\t| Subcellular Location | \t\t\tn/a | \t\t
\t\t\t\t\t| Residues | \t\t\tn/a | \t\t
\t\t\t\t\t| Formulation | \t\t\tSupplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. | \t\t
\t\t\t
\t\t\t| Subcellular Location | \t\t\tn/a | \t\t
\t\t\t
Subcellular Location | Subcellular LocationSubcellular Location\t\t\t
n/a | n/a\t\t\t\t
\t\t\t| Residues | \t\t\tn/a | \t\t
\t\t\t
Residues | ResiduesResidues\t\t\t
n/a | n/a\t\t\t\t
\t\t\t| Formulation | \t\t\tSupplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. | \t\t
\t\t\t
Formulation | FormulationFormulation\t\t\t
Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl. | Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl.\t\t\t
USAGE
USAGE
脱氧胞苷激酶(DCK)重组蛋白Reconstitute in sterile PBS, pH7.2-pH7.4.
脱氧胞苷激酶(DCK)重组蛋白脱氧胞苷激酶(DCK)重组蛋白Reconstitute in sterile PBS, pH7.2-pH7.4.
STORAGE AND STABILITY
STORAGE AND STABILITY
Storage:\xa0Avoid repeated freeze/thaw cycles. Store at 2-8oC for one month. Aliquot and store at -80oC for 12 months.
Stability Test:\xa0The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37oC for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
Storage:Storage:\xa0Avoid repeated freeze/thaw cycles. Store at 2-8
ooC for one month. Aliquot and store at -80
ooC for 12 months.
Stability Test:Stability Test:\xa0The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37
ooC for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
About the MARKER (complimentary)
About the MARKER (complimentary)
脱氧胞苷激酶(DCK)重组蛋白Effective Size Range:\xa010kDa to 70kDa.
Protein bands:\xa010kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and 70kDa.
Double intensity bands:\xa0The 26kDa, 18kDa, 10kDa bands are at double intensity to make location and size approximation of proteins of interest quick and easy.
Ready-to-use:\xa0No need to heat, dilute or add reducing agents before use.
脱氧胞苷激酶(DCK)重组蛋白脱氧胞苷激酶(DCK)重组蛋白
Effective Size Range:Effective Size Range:\xa010kDa to 70kDa.
Protein bands:Protein bands:\xa010kDa, 14kDa, 18kDa, 22kDa, 26kDa, 33kDa, 44kDa and 70kDa.
Double intensity bands:Double intensity bands:\xa0The 26kDa, 18kDa, 10kDa bands are at double intensity to make location and size approximation of proteins of interest quick and easy.
Ready-to-use:Ready-to-use:\xa0No need to heat, dilute or add reducing agents before use.yb-5857R\xa0\xa0 \xa0ADAMTS15整合素样金属蛋白酶与凝血酶15型抗体\xa0\xa0 \xa0浓度1mg/ml
yb-5858R\xa0\xa0 \xa0ADAMTS2整合素样金属蛋白酶与凝血酶2型抗体\xa0\xa0 \xa0浓度1mg/ml
yb-5859R\xa0\xa0 \xa0ADAMTS8整合素样金属蛋白酶与凝血酶8型抗体\xa0\xa0 \xa0浓度1mg/ml
yb-5860R\xa0\xa0 \xa0ADAMTS9整合素样金属蛋白酶与凝血酶9型抗体\xa0\xa0 \xa0浓度1mg/ml
yb-5919R\xa0\xa0 \xa0ARP4血管生成素样蛋白4抗体\xa0\xa0 \xa0浓度1mg/ml
yb-6588R\xa0\xa0 \xa0ADAMTS10整合素样金属蛋白酶与凝血酶10型抗体\xa0\xa0 \xa0浓度1mg/ml
yb-6587R\xa0\xa0 \xa0APEX2嘌呤嘧啶核酸内切酶2抗体\xa0\xa0 \xa0浓度1mg/ml
yb-0720M\xa0\xa0 \xa0AD7C-NTP神经丝蛋白抗体\xa0\xa0 \xa0浓度1mg/ml
yb-0105M\xa0\xa0 \xa0beta Amyloid 1-28β淀粉样肽(1-28)抗体\xa0\xa0 \xa0浓度1mg/ml
yb-2445R\xa0\xa0 \xa0Aurora B有丝分裂激酶B抗体\xa0\xa0 \xa0浓度1mg/ml
yb-3573R\xa0\xa0 \xa0Aggrecanase-2软骨蛋白聚糖抗体\xa0\xa0 \xa0浓度1mg/ml
yb-3574R\xa0\xa0 \xa0ADAM10去整合素样金属蛋白酶10抗体\xa0\xa0 \xa0浓度1mg/ml
yb-9131R\xa0\xa0 \xa0ASB9含锚蛋白重复序列-细胞因子信号抑制物盒蛋白家族9抗体\xa0\xa0 \xa0浓度1mg/ml
yb-9132R\xa0\xa0 \xa0ASB8含锚蛋白重复序列-细胞因子信号抑制物盒蛋白家族8抗体\xa0\xa0 \xa0浓度1mg/ml
yb-4731R\xa0\xa0 \xa0ABP1植物生长激素ABP1抗体\xa0\xa0 \xa0浓度1mg/ml
yb-9309R\xa0\xa0 \xa0ACTR1A肌动蛋白相关蛋白1抗体\xa0\xa0 \xa0浓度1mg/ml
yb-9518R\xa0\xa0 \xa0AHSPα红细胞分化相关因子抗体\xa0\xa0 \xa0浓度1mg/ml
yb-9885R\xa0\xa0 \xa0ATP1血管紧张素激活蛋白1抗体\xa0\xa0 \xa0浓度1mg/ml
yb-15585R\xa0\xa0 \xa0AFMAlpha清蛋白抗体\xa0\xa0 \xa0浓度1mg/ml
yb-11020R\xa0\xa0 \xa0AFAP1L2AFAP1L2抗体\xa0\xa0 \xa0浓度1mg/ml
yb-13624R\xa0\xa0 \xa0AHNAK神经细胞分化相关蛋白AHNAK抗体\xa0\xa0 \xa0浓度1mg/ml
yb-13713R\xa0\xa0 \xa0AJAP1粘合连接相关蛋白1抗体\xa0\xa0 \xa0浓度1mg/ml
yb-13736R\xa0\xa0 \xa0ADAM13去整合素样金属蛋白酶13抗体\xa0\xa0 \xa0浓度1mg/ml
yb-10219R\xa0\xa0 \xa0Agrin聚集蛋白抗体\xa0\xa0 \xa0浓度1mg/ml